33,898 XNAS Volume
XNAS 19 Mar, 2025 11:34 AM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Warren G. Nighan | SVP Quality and Regulatory | Sale of securities on an exchange or to another person at price $ 12.31 per share. | 16 Jan 2025 | 4,060 | 41,817 (0%) | 0% | 12.3 | 49,979 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Purchase of securities on an exchange or from another person at price $ 5.86 per share. | 08 Oct 2024 | 1,700 | 172,711 (0%) | 0% | 5.9 | 9,962 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 6.03 per share. | 07 Oct 2024 | 20,000 | 681,582 (1%) | 0% | 6.0 | 120,600 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Purchase of securities on an exchange or from another person at price $ 6.08 per share. | 07 Oct 2024 | 100 | 45,877 (0%) | 0% | 6.1 | 608 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Purchase of securities on an exchange or from another person at price $ 6.09 per share. | 07 Oct 2024 | 768 | 45,777 (0%) | 0% | 6.1 | 4,677 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 2,982 | 637,405 (1%) | 0% | 7.1 | 21,262 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 3,372 | 634,033 (1%) | 0% | 7.1 | 24,042 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 277 | 40,998 (0%) | 0% | 7.1 | 1,975 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 251 | 41,275 (0%) | 0% | 7.1 | 1,790 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 667 | 166,470 (0%) | 0% | 7.1 | 4,756 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 717 | 167,137 (0%) | 0% | 7.1 | 5,112 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 395 | 63,587 (0%) | 0% | 7.1 | 2,816 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 359 | 63,982 (0%) | 0% | 7.1 | 2,560 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 413 | 38,052 (0%) | 0% | 7.1 | 2,945 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.13 per share. | 20 Jul 2024 | 616 | 38,465 (0%) | 0% | 7.1 | 4,392 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 19 Jul 2024 | 8,307 | 636,570 (1%) | 0% | 7.2 | 59,644 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 19 Jul 2024 | 735 | 41,526 (0%) | 0% | 7.2 | 5,277 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 19 Jul 2024 | 1,025 | 64,341 (0%) | 0% | 7.2 | 7,360 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 19 Jul 2024 | 1,983 | 39,081 (0%) | 0% | 7.2 | 14,238 | Common Stock |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 7,466 | 7,466 | - | - | Non-Qualified Stock Option (right to buy) | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 7,633 | 7,633 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2024 | 3,817 | 640,387 (1%) | 0% | 0 | Common Stock | |
| Eileen O'Shea Auen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 87,043 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 149,376 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 125,863 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 207,693 | 207,693 | - | - | Non-Qualified Stock Option (right to buy) | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 211,622 | 211,622 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 105,811 | 644,877 (1%) | 0% | 0 | Common Stock | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 23,952 | 23,952 | - | - | Performance Right | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 23,507 | 23,507 | - | - | Non-Qualified Stock Option (right to buy) | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 18,733 | 42,261 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 76,458 | 76,458 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 77,905 | 77,905 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 38,953 | 167,854 (0%) | 0% | 0 | Common Stock | |
| Jan Stern Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 87,359 (0%) | 0% | 0 | Common Stock | |
| Michael E. Tarnoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 65,703 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 12,350 | 65,366 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 24,240 | 24,240 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 24,699 | 24,699 | - | - | Performance Right | |
| Karen A. Licitra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 72,760 (0%) | 0% | 0 | Common Stock | |
| Lorinda A. Burgess | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 20,541 | 37,582 (0%) | 0% | 0 | Common Stock | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 21,971 | 41,064 (0%) | 0% | 0 | Common Stock | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 30,428 | 30,428 | - | - | Performance Right | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2024 | 29,863 | 29,863 | - | - | Non-Qualified Stock Option (right to buy) | |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 56,279 | 690,312 (1%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.40 per share. | 17 Jul 2024 | 28,730 | 661,582 (1%) | 0% | 7.4 | 212,602 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 52,378 | 0 | - | - | Performance Right | |
| Warren G. Nighan | SVP Quality and Regulatory | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 5,677 | 46,675 (0%) | 0% | 0 | Common Stock | |
| Warren G. Nighan | SVP Quality and Regulatory | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.40 per share. | 17 Jul 2024 | 1,666 | 45,009 (0%) | 0% | 7.4 | 12,328 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 7,550 | 0 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.18 per share. | 17 Jul 2024 | 2,585 | 171,011 (0%) | 0% | 7.2 | 18,560 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 11,142 | 177,612 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.40 per share. | 17 Jul 2024 | 4,016 | 173,596 (0%) | 0% | 7.4 | 29,718 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 14,817 | 0 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 6,600 | 70,187 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.40 per share. | 17 Jul 2024 | 2,379 | 67,808 (0%) | 0% | 7.4 | 17,605 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 8,777 | 0 | - | - | Performance Right | |
| Laura Piccinini | SVP International | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 4,439 | 42,491 (0%) | 0% | 0 | Common Stock | |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.40 per share. | 17 Jul 2024 | 2,485 | 40,006 (0%) | 0% | 7.4 | 18,389 | Common Stock |
| Laura Piccinini | SVP International | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jul 2024 | 5,903 | 0 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 6.70 per share. | 08 Apr 2024 | 10,000 | 539,066 (1%) | 0% | 6.7 | 67,000 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 4.67 per share. | 29 Feb 2024 | 1,927 | 128,901 (0%) | 0% | 4.7 | 8,999 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 3,372 | 529,066 (1%) | 0% | 8.7 | 29,168 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 2,982 | 532,438 (1%) | 0% | 8.7 | 26,063 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 365 | 28,289 (0%) | 0% | 8.6 | 3,157 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 332 | 28,654 (0%) | 0% | 8.7 | 2,902 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 667 | 114,595 (0%) | 0% | 8.7 | 5,770 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 717 | 115,262 (0%) | 0% | 8.7 | 6,267 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 395 | 47,509 (0%) | 0% | 8.7 | 3,417 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 359 | 47,904 (0%) | 0% | 8.7 | 3,138 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 255 | 58,128 (0%) | 0% | 8.7 | 2,206 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 333 | 58,383 (0%) | 0% | 8.7 | 2,910 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.74 per share. | 20 Jul 2023 | 616 | 19,506 (0%) | 0% | 8.7 | 5,384 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.65 per share. | 20 Jul 2023 | 413 | 19,093 (0%) | 0% | 8.6 | 3,572 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 11,379 | 549,259 (1%) | 0% | 8.9 | 101,501 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 31,572 | 560,638 (1%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 108,871 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 1,575 | 31,085 (0%) | 0% | 8.9 | 14,049 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 15,081 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 4,371 | 32,660 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 3,159 | 120,205 (0%) | 0% | 8.9 | 28,178 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 8,769 | 123,364 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 30,242 | 0 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 13,453 | 0 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 3,900 | 51,409 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 1,404 | 50,005 (0%) | 0% | 8.9 | 12,524 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.92 per share. | 19 Jul 2023 | 1,230 | 60,313 (0%) | 0% | 8.9 | 10,972 | Common Stock |
| Scott Centea | SVP/GM, VIT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 11,782 | 0 | - | - | Performance Right | |
| Scott Centea | SVP/GM, VIT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jul 2023 | 3,415 | 61,543 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 4,906 | 445,501 (1%) | 0% | 9.6 | 47,245 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 2,262 | 443,239 (1%) | 0% | 9.6 | 21,625 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 313 | 18,197 (0%) | 0% | 9.6 | 2,992 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 679 | 18,510 (0%) | 0% | 9.6 | 6,539 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 376 | 87,288 (0%) | 0% | 9.6 | 3,595 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 1,362 | 87,664 (0%) | 0% | 9.6 | 13,116 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 596 | 37,158 (0%) | 0% | 9.6 | 5,739 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 279 | 36,879 (0%) | 0% | 9.6 | 2,667 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.56 per share. | 14 Jul 2023 | 351 | 48,128 (0%) | 0% | 9.6 | 3,356 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.63 per share. | 14 Jul 2023 | 517 | 48,479 (0%) | 0% | 9.6 | 4,979 | Common Stock |
| Laura Piccinini | SVP International | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.64 per share. | 01 Jun 2023 | 1,400 | 5,954 (0%) | 0% | 9.6 | 13,496 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.43 per share. | 03 Feb 2023 | 555 | 89,026 (0%) | 0% | 13.4 | 7,454 | Common Stock |
| Richard C. Rosenzweig | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.36 per share. | 01 Feb 2023 | 1,137 | 15,730 (0%) | 0% | 13.4 | 15,190 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 12.95 per share. | 31 Jan 2023 | 4,633 | 19,189 (0%) | 0% | 12.9 | 59,997 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Purchase of securities on an exchange or from another person at price $ 13.82 per share. | 12 Oct 2022 | 1,083 | 89,581 (0%) | 0% | 13.8 | 14,967 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 10 Oct 2022 | 10,000 | 450,407 (1%) | 0% | 15 | 150,000 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 29 Jul 2022 | 5,000 | 23,822 (0%) | 0% | 22.4 | 112,200 | Common Stock |
| Eileen O'Shea Auen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 49,461 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 122,978 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 111,794 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 88,281 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 66,187 | 66,187 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 33,094 | 440,407 (1%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 77,530 | 77,530 | - | - | Non- Qualified Stock Option (right to buy) | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 8,027 | 8,027 | - | - | Non- Qualified Stock Option (right to buy) | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 6,852 | 6,852 | - | - | Performance Right | |
| Warren G. Nighan | SVP Quality and Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,426 | 39,619 (0%) | 0% | 0 | Common Stock | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 8,646 | 8,646 | - | - | Non-Qualified Stock Option (right to buy) | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,381 | 7,381 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,691 | 28,822 (0%) | 0% | 0 | Common Stock | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 9,283 | 9,283 | - | - | Non- Qualified Stock Option (right to buy) | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,925 | 7,925 | - | - | Performance Right | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,963 | 16,867 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 18,650 | 18,650 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 15,922 | 15,922 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,961 | 88,498 (0%) | 0% | 0 | Common Stock | |
| Jan Stern Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 49,777 (0%) | 0% | 0 | Common Stock | |
| Michael E. Tarnoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 28,121 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,974 | 7,974 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 9,341 | 9,341 | - | - | Non- Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,987 | 37,754 (0%) | 0% | 0 | Common Stock | |
| Karen A. Licitra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,060 | 35,178 (0%) | 0% | 0 | Common Stock | |
| Scott Centea | SVP/GM, VIT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 7,410 | 7,410 | - | - | Performance Right | |
| Scott Centea | SVP/GM, VIT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 3,705 | 48,996 (0%) | 0% | 0 | Common Stock | |
| Scott Centea | SVP/GM, VIT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 8,680 | 8,680 | - | - | Non- Qualified Stock Option (right to buy) | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 8,803 | 8,803 | - | - | Performance Right | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 4,402 | 7,354 (0%) | 0% | 0 | Common Stock | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2022 | 10,312 | 10,312 | - | - | Non- Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.32 per share. | 15 Jul 2022 | 4,505 | 81,221 (0%) | 0% | 21.3 | 96,047 | Common Stock |
| Wesley E. Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 6,022 | 0 | - | - | Non- Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.95 per share. | 15 Jul 2022 | 6,022 | 85,726 (0%) | 0% | 16.0 | 96,051 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.95 per share. | 15 Jul 2022 | 14,758 | 92,935 (0%) | 0% | 15.9 | 235,390 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2022 | 14,758 | 0 | - | - | Non- Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.32 per share. | 15 Jul 2022 | 12,398 | 80,537 (0%) | 0% | 21.3 | 264,325 | Common Stock |
| Dennis S. Meteny | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.95 per share. | 12 Jul 2022 | 6,022 | 120,716 (0%) | 0% | 16.0 | 96,051 | Common Stock |
| Dennis S. Meteny | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2022 | 6,022 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dennis S. Meteny | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.02 per share. | 12 Jul 2022 | 4,798 | 115,918 (0%) | 0% | 20.0 | 96,056 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 25,123 | 415,887 (1%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 50,139 | 0 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 8,574 | 407,313 (1%) | 0% | 20.5 | 176,110 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 919 | 36,193 (0%) | 0% | 20.5 | 18,876 | Common Stock |
| Warren G. Nighan | SVP Quality and Regulatory | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 3,233 | 37,112 (0%) | 0% | 0 | Common Stock | |
| Warren G. Nighan | SVP Quality and Regulatory | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 6,452 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 3,480 | 26,354 (0%) | 0% | 0 | Common Stock | |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 6,945 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 1,223 | 25,131 (0%) | 0% | 20.5 | 25,120 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 8,357 | 0 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 1,509 | 78,177 (0%) | 0% | 20.5 | 30,995 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 4,188 | 79,686 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 3,104 | 34,845 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jul 2022 | 6,195 | 0 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.54 per share. | 07 Jul 2022 | 1,078 | 33,767 (0%) | 0% | 20.5 | 22,142 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 22.44 per share. | 28 Apr 2022 | 3,513 | 22,874 (0%) | 0% | 22.4 | 78,832 | Common Stock |
| Howard W. Donnelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Apr 2022 | 6,022 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Howard W. Donnelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.95 per share. | 20 Apr 2022 | 6,022 | 104,734 (0%) | 0% | 16.0 | 96,051 | Common Stock |
| Wesley E. Johnson | Director | Sale of securities on an exchange or to another person at price $ 23.26 per share. | 11 Apr 2022 | 1,299 | 79,704 (0%) | 0% | 23.3 | 30,215 | Common Stock |
| Wesley E. Johnson | Director | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 11 Apr 2022 | 6,201 | 80,003 (0%) | 0% | 23 | 142,623 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.48 per share. | 03 Feb 2022 | 583 | 75,498 (0%) | 0% | 20.5 | 11,940 | Common Stock |
| Richard C. Rosenzweig | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.31 per share. | 01 Feb 2022 | 1,194 | 12,904 (0%) | 0% | 21.3 | 25,444 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Purchase of securities on an exchange or from another person at price $ 22.64 per share. | 12 Jan 2022 | 1,000 | 76,081 (0%) | 0% | 22.6 | 22,640 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 22.84 per share. | 11 Jan 2022 | 10,000 | 390,764 (1%) | 0% | 22.8 | 228,400 | Common Stock |
| Scott Centea | Sr. VP/GM, Global VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.37 per share. | 31 Oct 2021 | 953 | 45,291 (0%) | 0% | 29.4 | 27,990 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 27.97 per share. | 20 Oct 2021 | 3,494 | 26,387 (0%) | 0% | 28.0 | 97,727 | Common Stock |
| Scott Centea | Sr. VP/GM, Global VIT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.77 per share. | 15 Oct 2021 | 12,000 | 58,244 (0%) | 0% | 16.8 | 201,240 | Common Stock |
| Scott Centea | Sr. VP/GM, Global VIT | Sale of securities on an exchange or to another person at price $ 27.92 per share. | 15 Oct 2021 | 12,000 | 46,244 (0%) | 0% | 27.9 | 335,040 | Common Stock |
| Scott Centea | Sr. VP/GM, Global VIT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2021 | 12,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.59 per share. | 05 Oct 2021 | 10,748 | 42,489 (0%) | 0% | 16.6 | 178,309 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 10,748 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Sale of securities on an exchange or to another person at price $ 27.15 per share. | 05 Oct 2021 | 10,748 | 31,741 (0%) | 0% | 27.1 | 291,808 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 40,528 | 399,695 (1%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.29 per share. | 12 Aug 2021 | 21,532 | 378,163 (1%) | 0% | 27.3 | 587,608 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 34,938 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 11,406 | 33,228 (0%) | 0% | 0 | Common Stock | |
| David D. Helsel | SVP Global Operations and R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 9,834 | 0 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.29 per share. | 12 Aug 2021 | 3,347 | 29,881 (0%) | 0% | 27.3 | 91,340 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 9,437 | 0 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.29 per share. | 12 Aug 2021 | 4,173 | 75,081 (0%) | 0% | 27.3 | 113,881 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 10,946 | 79,254 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.29 per share. | 12 Aug 2021 | 3,130 | 31,741 (0%) | 0% | 27.3 | 85,418 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 8,210 | 34,871 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2021 | 7,079 | 0 | - | - | Performance Right | |
| Dennis S. Meteny | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.64 per share. | 28 Jul 2021 | 5,726 | 117,865 (0%) | 0% | 14.6 | 83,829 | Common Stock |
| Dennis S. Meteny | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.43 per share. | 28 Jul 2021 | 3,171 | 114,694 (0%) | 0% | 26.4 | 83,810 | Common Stock |
| Dennis S. Meteny | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 5,726 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.64 per share. | 28 Jul 2021 | 5,726 | 89,375 (0%) | 0% | 14.6 | 83,829 | Common Stock |
| Wesley E. Johnson | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2021 | 5,726 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.43 per share. | 28 Jul 2021 | 3,171 | 86,204 (0%) | 0% | 26.4 | 83,810 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 26 Jul 2021 | 2,105 | 359,167 (0%) | 0% | 26.1 | 54,941 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 26 Jul 2021 | 353 | 68,308 (0%) | 0% | 26.1 | 9,213 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 26 Jul 2021 | 318 | 26,661 (0%) | 0% | 26.1 | 8,300 | Common Stock |
| Scott Centea | Sr. VP/GM, Global VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 26 Jul 2021 | 419 | 46,244 (0%) | 0% | 26.1 | 10,936 | Common Stock |
| Eileen O'Shea Auen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 42,401 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 112,139 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 98,712 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 83,649 (0%) | 0% | 0 | Common Stock | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 8,418 | 8,418 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 6,197 | 6,197 | - | - | Peformance Right | |
| Jan Stern Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 42,717 (0%) | 0% | 0 | Common Stock | |
| Michael E. Tarnoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 21,061 (0%) | 0% | 0 | Common Stock | |
| Karen A. Licitra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,738 | 28,118 (0%) | 0% | 0 | Common Stock | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 5,903 | 5,903 | - | - | Performance Right | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 8,019 | 8,019 | - | - | Non-Qualified Stock Option (right to buy) | |
| Laura Piccinini | SVP International | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jul 2021 | 2,952 | 2,952 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 37,420 | 372,503 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 101,667 | 101,667 | - | - | Non-Qualified Stock Option (right to buy) | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 74,840 | 74,840 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 11,026 | 11,026 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 20,128 | 20,128 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 11,923 | 11,923 | - | - | Non-Qualified Stock Option (right to buy) | |
| Scott Centea | SVP/GM, VIT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 5,684 | 5,684 | - | - | Performance Right | |
| Scott Centea | SVP/GM, VIT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2021 | 7,721 | 7,721 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2021 | 13,625 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.21 per share. | 15 Apr 2021 | 10,080 | 63,291 (0%) | 0% | 24.2 | 244,037 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.07 per share. | 15 Apr 2021 | 13,625 | 73,371 (0%) | 0% | 14.1 | 191,704 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Sale of securities on an exchange or to another person at price $ 23.93 per share. | 14 Apr 2021 | 3,500 | 19,115 (0%) | 0% | 23.9 | 83,755 | Common Stock |
| Howard W. Donnelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.64 per share. | 01 Apr 2021 | 5,726 | 96,595 (0%) | 0% | 14.6 | 83,829 | Common Stock |
| Howard W. Donnelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2021 | 5,726 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Howard W. Donnelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.15 per share. | 01 Apr 2021 | 3,621 | 92,974 (0%) | 0% | 23.1 | 83,826 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.24 per share. | 03 Feb 2021 | 527 | 59,746 (0%) | 0% | 19.2 | 10,139 | Common Stock |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 62,000 | 62,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard C. Rosenzweig | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 11,000 | 11,000 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | Director | Sale of securities on an exchange or to another person at price $ 18.53 per share. | 20 Jan 2021 | 6,500 | 77,911 (0%) | 0% | 18.5 | 120,445 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.29 per share. | 18 Dec 2020 | 733 | 22,615 (0%) | 0% | 14.3 | 10,475 | Common Stock |
| Scott Centea | SVP/GM, VIT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.62 per share. | 31 Oct 2020 | 849 | 45,004 (0%) | 0% | 10.6 | 9,016 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Purchase of securities on an exchange or from another person at price $ 9.38 per share. | 11 Aug 2020 | 1,013 | 60,273 (0%) | 0% | 9.4 | 9,502 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 8.26 per share. | 31 Jul 2020 | 40,000 | 343,319 (0%) | 0% | 8.3 | 330,400 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 1,799 | 303,319 (0%) | 0% | 8.8 | 15,831 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 1,876 | 305,118 (0%) | 0% | 8.8 | 16,509 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 314 | 59,552 (0%) | 0% | 8.8 | 2,763 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 292 | 59,260 (0%) | 0% | 8.8 | 2,570 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 259 | 23,724 (0%) | 0% | 8.8 | 2,279 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.80 per share. | 26 Jul 2020 | 283 | 23,983 (0%) | 0% | 8.8 | 2,490 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 1,483 | 306,994 (0%) | 0% | 9.2 | 13,658 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.46 per share. | 17 Jul 2020 | 2,131 | 308,477 (0%) | 0% | 9.5 | 20,159 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 207 | 23,501 (0%) | 0% | 9.2 | 1,906 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.46 per share. | 17 Jul 2020 | 254 | 23,708 (0%) | 0% | 9.5 | 2,403 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 155 | 23,348 (0%) | 0% | 9.2 | 1,428 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 152 | 59,866 (0%) | 0% | 9.2 | 1,400 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 248 | 60,018 (0%) | 0% | 9.2 | 2,284 | Common Stock |
| Stephen A. Trowbridge | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.46 per share. | 17 Jul 2020 | 354 | 60,266 (0%) | 0% | 9.5 | 3,349 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 224 | 24,342 (0%) | 0% | 9.2 | 2,063 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.46 per share. | 17 Jul 2020 | 262 | 24,566 (0%) | 0% | 9.5 | 2,479 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.21 per share. | 17 Jul 2020 | 76 | 24,266 (0%) | 0% | 9.2 | 700 | Common Stock |
| Eileen O'Shea Auen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 36,663 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 106,401 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 90,869 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Gould | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 77,504 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 84,411 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 108,871 | 108,871 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 54,435 | 310,608 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 160,237 | 160,237 | - | - | Non-Qualified Stock Option (right to buy) | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 22,196 | 22,196 | - | - | Non-Qualified Stock Option (right to buy) | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,081 | 15,081 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 7,540 | 23,962 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 30,242 | 30,242 | - | - | Performance Right | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,121 | 60,620 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 44,510 | 44,510 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jan Stern Reed | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 36,979 (0%) | 0% | 0 | Common Stock | |
| Michael E. Tarnoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 15,323 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 13,453 | 13,453 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 19,800 | 19,800 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 6,726 | 24,828 (0%) | 0% | 0 | Common Stock | |
| Karen A. Licitra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2020 | 15,323 | 22,380 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.21 per share. | 23 May 2020 | 826 | 18,102 (0%) | 0% | 11.2 | 9,259 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.23 per share. | 04 Apr 2020 | 4,245 | 256,173 (0%) | 0% | 10.2 | 43,426 | Common Stock |
| Brent J. Boucher | SVP and GM of Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.99 per share. | 12 Feb 2020 | 490 | 15,416 (0%) | 0% | 13.0 | 6,365 | Common Stock |
| Stephen A. Trowbridge | EVP, General Counsel and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 18,204 | 18,204 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | EVP, General Counsel and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2020 | 5,376 | 45,499 (0%) | 0% | 0 | Common Stock | |
| Brent J. Boucher | SVP and GM of Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.48 per share. | 17 Jan 2020 | 490 | 15,906 (0%) | 0% | 15.5 | 7,585 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.57 per share. | 18 Dec 2019 | 736 | 16,422 (0%) | 0% | 15.6 | 11,460 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 14.19 per share. | 25 Oct 2019 | 15,000 | 260,418 (0%) | 0% | 14.2 | 212,850 | Common Stock |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 50,139 | 50,139 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 15,320 | 15,320 | - | - | Performance Right | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 6,945 | 6,945 | - | - | Performance Right | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 8,357 | 8,357 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 6,195 | 6,195 | - | - | Performance Right | |
| Brent J. Boucher | SVP and GM of Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2019 | 6,452 | 6,452 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.10 per share. | 18 Aug 2019 | 826 | 33,438 (0%) | 0% | 19.1 | 15,777 | Common Stock |
| Wesley E. Johnson | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.83 per share. | 06 Aug 2019 | 3,581 | 69,088 (0%) | 0% | 19.8 | 71,011 | Common Stock |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2019 | 6,650 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 06 Aug 2019 | 6,650 | 72,669 (0%) | 0% | 10.7 | 71,022 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.89 per share. | 26 Jul 2019 | 1,826 | 143,310 (0%) | 0% | 20.9 | 38,145 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.91 per share. | 26 Jul 2019 | 1,752 | 141,558 (0%) | 0% | 20.9 | 36,634 | Common Stock |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.89 per share. | 26 Jul 2019 | 511 | 27,304 (0%) | 0% | 20.9 | 10,675 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.91 per share. | 26 Jul 2019 | 252 | 18,928 (0%) | 0% | 20.9 | 5,269 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.89 per share. | 26 Jul 2019 | 276 | 19,180 (0%) | 0% | 20.9 | 5,766 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.89 per share. | 26 Jul 2019 | 309 | 15,441 (0%) | 0% | 20.9 | 6,455 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.91 per share. | 22 Jul 2019 | 285 | 37,723 (0%) | 0% | 20.9 | 5,959 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.89 per share. | 22 Jul 2019 | 306 | 38,008 (0%) | 0% | 20.9 | 6,392 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.38 per share. | 22 Jul 2019 | 355 | 38,314 (0%) | 0% | 21.4 | 7,590 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 1,444 | 145,136 (0%) | 0% | 21.5 | 31,089 | Common Stock |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 172 | 27,815 (0%) | 0% | 21.5 | 3,703 | Common Stock |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 404 | 27,987 (0%) | 0% | 21.5 | 8,698 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 172 | 17,158 (0%) | 0% | 21.5 | 3,703 | Common Stock |
| David D. Helsel | SVP Global Operations and R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 233 | 17,330 (0%) | 0% | 21.5 | 5,016 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.38 per share. | 18 Jul 2019 | 355 | 38,669 (0%) | 0% | 21.4 | 7,590 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 148 | 39,024 (0%) | 0% | 21.5 | 3,186 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 241 | 39,172 (0%) | 0% | 21.5 | 5,189 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 74 | 19,456 (0%) | 0% | 21.5 | 1,593 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 218 | 19,530 (0%) | 0% | 21.5 | 4,694 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 148 | 15,750 (0%) | 0% | 21.5 | 3,186 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 244 | 15,898 (0%) | 0% | 21.5 | 5,253 | Common Stock |
| Brent J. Boucher | SVP and GM of Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 148 | 16,396 (0%) | 0% | 21.5 | 3,186 | Common Stock |
| Brent J. Boucher | SVP and GM of Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.53 per share. | 18 Jul 2019 | 225 | 16,544 (0%) | 0% | 21.5 | 4,844 | Common Stock |
| Eileen O'Shea Auen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 21,340 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 91,078 (0%) | 0% | 0 | Common Stock | |
| Jeffrey G. Gold | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 83,640 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 75,546 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Gould | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 62,181 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 66,019 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 25,104 | 146,580 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 83,967 | 83,967 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 25,621 | 25,621 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,660 | 28,391 (0%) | 0% | 0 | Common Stock | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 3,473 | 17,563 (0%) | 0% | 0 | Common Stock | |
| David D. Helsel | SVP Global Operations and R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 11,615 | 11,615 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 13,975 | 13,975 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 4,178 | 39,413 (0%) | 0% | 0 | Common Stock | |
| Jan Stern Reed | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 21,656 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 3,098 | 19,748 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 10,361 | 10,361 | - | - | Non-Qualified Stock Option (right to buy) | |
| Brent J. Boucher | SVP and GM of Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 10,790 | 10,790 | - | - | Non-Qualified Stock Option (right to buy) | |
| Brent J. Boucher | SVP and GM of Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 3,226 | 16,769 (0%) | 0% | 0 | Common Stock | |
| Karen A. Licitra | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jul 2019 | 7,057 | 7,057 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.92 per share. | 16 Jul 2019 | 7,000 | 68,774 (0%) | 0% | 11.9 | 83,440 | Common Stock |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2019 | 7,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2019 | 6,650 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Kevin J. Gould | None | Sale of securities on an exchange or to another person at price $ 21.45 per share. | 16 Jul 2019 | 13,650 | 55,124 (0%) | 0% | 21.5 | 292,793 | Common Stock |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 16 Jul 2019 | 6,650 | 61,774 (0%) | 0% | 10.7 | 71,022 | Common Stock |
| Jeffrey G. Gold | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 3,276 | 76,583 (0%) | 0% | 21.7 | 71,024 | Common Stock |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 6,650 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 12 Jul 2019 | 6,650 | 79,859 (0%) | 0% | 10.7 | 71,022 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 200,000 | 341,558 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 96,140 | 245,418 (0%) | 0% | 21.7 | 2,084,315 | Common Stock |
| James C. Clemmer | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 250,000 | 0 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 10,400 | 37,704 (0%) | 0% | 0 | Common Stock | |
| Michael C. Greiner | EVP and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 20,000 | 0 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 3,440 | 34,264 (0%) | 0% | 21.7 | 74,579 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 1,185 | 40,123 (0%) | 0% | 21.7 | 25,691 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 6,894 | 0 | - | - | Performance Right | |
| Stephen A. Trowbridge | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 3,585 | 41,308 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 3,174 | 22,102 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 1,050 | 21,052 (0%) | 0% | 21.7 | 22,764 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 6,103 | 0 | - | - | Performance right | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.68 per share. | 12 Jul 2019 | 5,158 | 25,883 (0%) | 0% | 21.7 | 111,825 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 30,000 | 0 | - | - | Performance Right | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2019 | 15,600 | 31,041 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 28 Jun 2019 | 6,650 | 87,628 (0%) | 0% | 10.7 | 71,022 | Common Stock |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jun 2019 | 6,650 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dennis S. Meteny | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.69 per share. | 28 Jun 2019 | 3,607 | 84,021 (0%) | 0% | 19.7 | 71,022 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.15 per share. | 23 May 2019 | 858 | 16,650 (0%) | 0% | 19.2 | 16,431 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.95 per share. | 04 Apr 2019 | 4,232 | 121,476 (0%) | 0% | 22.9 | 97,124 | Common Stock |
| Brent J. Boucher | SVP and GM of Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.90 per share. | 12 Feb 2019 | 490 | 13,543 (0%) | 0% | 22.9 | 11,221 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.10 per share. | 31 Jan 2019 | 981 | 16,142 (0%) | 0% | 21.1 | 20,699 | Common Stock |
| Michael C. Greiner | EVP and CFO | Sale of securities on an exchange or to another person at price $ 21.53 per share. | 07 Nov 2018 | 1,939 | 20,731 (0%) | 0% | 21.5 | 41,747 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.42 per share. | 27 Jul 2018 | 1,752 | 125,708 (0%) | 0% | 21.4 | 37,528 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.42 per share. | 27 Jul 2018 | 285 | 36,554 (0%) | 0% | 21.4 | 6,105 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.42 per share. | 27 Jul 2018 | 252 | 17,508 (0%) | 0% | 21.4 | 5,398 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.88 per share. | 26 Jul 2018 | 1,826 | 127,460 (0%) | 0% | 21.9 | 39,953 | Common Stock |
| Michael C. Greiner | EVP and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.88 per share. | 26 Jul 2018 | 511 | 22,670 (0%) | 0% | 21.9 | 11,181 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.88 per share. | 26 Jul 2018 | 276 | 17,760 (0%) | 0% | 21.9 | 6,039 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.88 per share. | 26 Jul 2018 | 308 | 17,123 (0%) | 0% | 21.9 | 6,739 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.67 per share. | 22 Jul 2018 | 355 | 37,536 (0%) | 0% | 21.7 | 7,693 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.50 per share. | 22 Jul 2018 | 391 | 37,145 (0%) | 0% | 21.5 | 8,407 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.88 per share. | 22 Jul 2018 | 306 | 36,839 (0%) | 0% | 21.9 | 6,695 | Common Stock |
| Eileen O'Shea Auen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 14,283 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 80,978 (0%) | 0% | 0 | Common Stock | |
| Jeffrey G. Gold | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 73,209 (0%) | 0% | 0 | Common Stock | |
| Steven R. LaPorte | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 48,484 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 68,489 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Gould | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 55,124 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 58,962 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 17,469 | 129,286 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 34,938 | 34,938 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 55,651 | 55,651 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 13,975 | 13,975 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,988 | 23,181 (0%) | 0% | 0 | Common Stock | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 22,260 | 22,260 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 4,719 | 37,891 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 15,032 | 15,032 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 9,437 | 9,437 | - | - | Performance Right | |
| Jan Stern Reed | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 6,307 | 14,599 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 7,079 | 7,079 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 11,276 | 11,276 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 3,539 | 18,036 (0%) | 0% | 0 | Common Stock | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 9,496 | 9,496 | - | - | Performance Right | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 4,748 | 17,431 (0%) | 0% | 0 | Common Stock | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2018 | 15,126 | 15,126 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.50 per share. | 12 Jul 2018 | 1,175 | 38,935 (0%) | 0% | 20.5 | 24,088 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2018 | 3,556 | 40,110 (0%) | 0% | 0 | Common Stock | |
| Stephen A. Trowbridge | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2018 | 5,737 | 0 | - | - | Performance Right | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2018 | 7,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 06 Jul 2018 | 7,000 | 70,906 (0%) | 0% | 13.5 | 94,710 | Common Stock |
| Jeffrey G. Gold | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.65 per share. | 06 Jul 2018 | 4,004 | 66,902 (0%) | 0% | 23.7 | 94,695 | Common Stock |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jun 2018 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.77 per share. | 22 Jun 2018 | 8,319 | 52,655 (0%) | 0% | 22.8 | 189,424 | Common Stock |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 22 Jun 2018 | 14,000 | 60,974 (0%) | 0% | 13.5 | 189,420 | Common Stock |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 21 Jun 2018 | 14,000 | 83,127 (0%) | 0% | 13.5 | 189,420 | Common Stock |
| Dennis S. Meteny | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.40 per share. | 21 Jun 2018 | 8,456 | 74,671 (0%) | 0% | 22.4 | 189,414 | Common Stock |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2018 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2018 | 7,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.40 per share. | 21 Jun 2018 | 4,228 | 63,906 (0%) | 0% | 22.4 | 94,707 | Common Stock |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 21 Jun 2018 | 7,000 | 68,134 (0%) | 0% | 13.5 | 94,710 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.68 per share. | 21 Jun 2018 | 6,650 | 65,353 (0%) | 0% | 10.7 | 71,022 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2018 | 6,650 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Howard W. Donnelly | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 22.40 per share. | 21 Jun 2018 | 3,171 | 62,182 (0%) | 0% | 22.4 | 71,030 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.37 per share. | 23 May 2018 | 827 | 14,497 (0%) | 0% | 20.4 | 16,846 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 19.76 per share. | 24 Apr 2018 | 1,280 | 33,172 (0%) | 0% | 19.8 | 25,293 | Common Stock |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.41 per share. | 31 Jan 2018 | 1,056 | 12,683 (0%) | 0% | 17.4 | 18,385 | Common Stock |
| Howard W. Donnelly | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.42 per share. | 21 Nov 2017 | 10,873 | 58,703 (0%) | 0% | 17.4 | 189,408 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 21 Nov 2017 | 14,000 | 69,576 (0%) | 0% | 13.5 | 189,420 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard A. Stark | SVP, GM - Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.63 per share. | 15 Nov 2017 | 10,000 | 30,754 (0%) | 0% | 10.6 | 106,300 | Common Stock |
| Richard A. Stark | SVP, GM - Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.92 per share. | 15 Nov 2017 | 17,409 | 48,163 (0%) | 0% | 11.9 | 207,515 | Common Stock |
| Richard A. Stark | SVP, GM - Oncology | Sale of securities on an exchange or to another person at price $ 16.29 per share. | 15 Nov 2017 | 27,409 | 20,754 (0%) | 0% | 16.3 | 446,493 | Common Stock |
| Richard A. Stark | SVP, GM - Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2017 | 10,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard A. Stark | SVP, GM - Oncology | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2017 | 17,409 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2017 | 25,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.31 per share. | 12 Sep 2017 | 25,000 | 65,064 (0%) | 0% | 14.3 | 357,750 | Common Stock |
| Kevin J. Gould | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.09 per share. | 12 Sep 2017 | 19,776 | 45,288 (0%) | 0% | 18.1 | 357,748 | Common Stock |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.53 per share. | 12 Sep 2017 | 14,000 | 59,288 (0%) | 0% | 13.5 | 189,420 | Common Stock |
| Kevin J. Gould | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.09 per share. | 12 Sep 2017 | 10,471 | 48,817 (0%) | 0% | 18.1 | 189,420 | Common Stock |
| Kevin J. Gould | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard A. Stark | SVP, GM - Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.56 per share. | 06 Aug 2017 | 502 | 20,754 (0%) | 0% | 16.6 | 8,313 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.56 per share. | 06 Aug 2017 | 495 | 34,452 (0%) | 0% | 16.6 | 8,197 | Common Stock |
| Eileen O'Shea Auen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 7,976 (0%) | 0% | 0 | Common Stock | |
| Dennis S. Meteny | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 69,127 (0%) | 0% | 0 | Common Stock | |
| Steven R. LaPorte | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 42,177 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 55,576 (0%) | 0% | 0 | Common Stock | |
| Kevin J. Gould | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 40,064 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 46,974 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 44,184 | 44,184 | - | - | Performance Right | |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 22,092 | 113,775 (0%) | 0% | 0 | Common Stock | |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.36 per share. | 26 Jul 2017 | 1,958 | 111,817 (0%) | 0% | 16.4 | 32,033 | Common Stock |
| James C. Clemmer | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 77,627 | 77,627 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 21,762 | 21,762 | - | - | Non-Qualified Stock Option (right to buy) | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 12,387 | 12,387 | - | - | Performance Right | |
| Michael C. Greiner | EVP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 6,193 | 16,193 (0%) | 0% | 0 | Common Stock | |
| Jan Stern Reed | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,976 | 8,292 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 6,684 | 6,684 | - | - | Performance Right | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 3,342 | 15,606 (0%) | 0% | 0 | Common Stock | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.36 per share. | 26 Jul 2017 | 282 | 15,324 (0%) | 0% | 16.4 | 4,614 | Common Stock |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 11,744 | 11,744 | - | - | Non-Qualified Stock Option (right to buy) | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 3,739 | 13,739 (0%) | 0% | 0 | Common Stock | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 7,477 | 7,477 | - | - | Performance Right | |
| Robert Arthur Simpson | SVP/GM, Global Vascular | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2017 | 13,137 | 13,137 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dennis S. Meteny | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 25 Jul 2017 | 12,879 | 70,248 (0%) | 0% | 17.1 | 220,488 | Common Stock |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 25 Jul 2017 | 14,000 | 83,127 (0%) | 0% | 15.8 | 220,500 | Common Stock |
| Dennis S. Meteny | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 25 Jul 2017 | 14,000 | 66,037 (0%) | 0% | 15.8 | 220,500 | Common Stock |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 25 Jul 2017 | 12,879 | 53,158 (0%) | 0% | 17.1 | 220,488 | Common Stock |
| Jeffrey G. Gold | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jul 2017 | 7,976 | 61,134 (0%) | 0% | 0 | Common Stock | |
| Wesley E. Johnson | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 25 Jul 2017 | 12,879 | 48,095 (0%) | 0% | 17.1 | 220,488 | Common Stock |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jul 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Wesley E. Johnson | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 25 Jul 2017 | 14,000 | 60,974 (0%) | 0% | 15.8 | 220,500 | Common Stock |
| Jan Stern Reed | None | Purchase of securities on an exchange or from another person at price $ 16.00 per share. | 24 Jul 2017 | 316 | 316 (0%) | 0% | 16 | 5,056 | Common Stock |
| Richard A. Stark | SVP, GM - Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 7,296 | 7,296 | - | - | Performance Right | |
| Richard A. Stark | SVP, GM - Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 12,818 | 12,818 | - | - | Non-Qualified Stock Option (right to buy) | |
| Richard A. Stark | SVP, GM - Oncology | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 3,648 | 21,256 (0%) | 0% | 0 | Common Stock | |
| Richard A. Stark | SVP, GM - Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 22 Jul 2017 | 432 | 17,608 (0%) | 0% | 17.1 | 7,396 | Common Stock |
| Richard A. Stark | SVP, GM - Oncology | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.80 per share. | 22 Jul 2017 | 393 | 18,040 (0%) | 0% | 16.8 | 6,602 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.80 per share. | 22 Jul 2017 | 397 | 31,679 (0%) | 0% | 16.8 | 6,670 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.12 per share. | 22 Jul 2017 | 437 | 31,242 (0%) | 0% | 17.1 | 7,481 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 7,409 | 7,409 | - | - | Performance Right | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 13,018 | 13,018 | - | - | Non-Qualified Stock Option (right to buy) | |
| Stephen A. Trowbridge | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2017 | 3,705 | 34,947 (0%) | 0% | 0 | Common Stock | |
| Howard W. Donnelly | None | Purchase of securities on an exchange or from another person at price $ 15.72 per share. | 21 Jul 2017 | 5,000 | 47,600 (0%) | 0% | 15.7 | 78,600 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 15.79 per share. | 20 Jul 2017 | 5,000 | 91,683 (0%) | 0% | 15.8 | 78,950 | Common Stock |
| James C. Clemmer | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 15.64 per share. | 20 Jul 2017 | 20,000 | 86,683 (0%) | 0% | 15.6 | 312,800 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 19 Jun 2017 | 14,000 | 56,144 (0%) | 0% | 15.8 | 220,500 | Common Stock |
| Howard W. Donnelly | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.28 per share. | 19 Jun 2017 | 13,544 | 42,600 (0%) | 0% | 16.3 | 220,496 | Common Stock |
| Howard W. Donnelly | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Chad Thomas Campbell | SVP/GM, Vascular Access | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.82 per share. | 23 May 2017 | 788 | 12,264 (0%) | 0% | 15.8 | 12,466 | Common Stock |
| Stephen A. Trowbridge | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.78 per share. | 24 Apr 2017 | 1,585 | 32,076 (0%) | 0% | 15.8 | 25,011 | Common Stock |
| David F. Burgstahler | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 12 Apr 2017 | 1,456,947 | 1,446,413 (3%) | 3% | 16 | 23,311,152 | Common Stock |
| David F. Burgstahler | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 12 Apr 2017 | 384,184 | 381,406 (1%) | 1% | 16 | 6,146,944 | Common Stock |
| David F. Burgstahler | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 16.00 per share. | 12 Apr 2017 | 508,869 | 505,189 (1%) | 1% | 16 | 8,141,904 | Common Stock |
| James C. Clemmer | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.06 per share. | 04 Apr 2017 | 4,508 | 66,683 (0%) | 0% | 17.1 | 76,906 | Common Stock |
| Steven R. LaPorte | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.75 per share. | 13 Jan 2017 | 14,000 | 48,201 (0%) | 0% | 15.8 | 220,500 | Common Stock |
| Steven R. LaPorte | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.92 per share. | 13 Jan 2017 | 14,000 | 34,201 (0%) | 0% | 17.9 | 250,880 | Common Stock |
| Steven R. LaPorte | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2017 | 14,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| David F. Burgstahler | Director, Ten Percent Owner | Other type of transaction at price $ 0.00 per share. | 18 Nov 2016 | 408,706 | 765,590 | - | - | Common Stock | |
| David F. Burgstahler | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Nov 2016 | 541,349 | 1,014,058 | - | - | Common Stock | |
| David F. Burgstahler | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.00 per share. | 18 Nov 2016 | 1,549,945 | 2,903,360 | - | - | Common Stock | |
| Eileen O'Shea Auen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2016 | 25,000 | 25,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jan Stern Reed | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2016 | 25,000 | 25,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Sale or transfer of securities back to the company at price $ 0.00 per share. | 31 Aug 2016 | 12,000 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Jeffrey G. Gold | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Aug 2016 | 9,642 | 52,037 | - | - | Common Stock | |
| Jeffrey G. Gold | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2016 | 12,000 | 61,679 | - | - | Common Stock | |
| Dennis S. Meteny | None | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 31 Aug 2016 | 9,642 | 61,151 | - | - | Common Stock |